Linked Life Data

12845340

Source:http://linkedlifedata.com/resource/pubmed/id/12845340

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2003-7-7
pubmed:abstractText
Omapatrilat is the most clinically advanced member of a new class of cardiovascular agents known as vasopeptidase inhibitors. Omapatrilat acts by inhibiting two key enzymes responsible for blood pressure regulation: neutral endopeptidase and angiotensin-converting enzyme. Omapatrilat provides dose-related reductions in systolic and diastolic blood pressure with an excellent trough-to-peak ratio after once-daily administration. The reduction in blood pressure is proportional to baseline blood pressure. Used in monotherapy, omapatrilat controls hypertension in more than 65% of patients treated and reduces blood pressure to a greater extent than existing agents. Furthermore, omapatrilat exhibits an excellent tolerability profile. Therefore, this drug represents an important new approach for treating a wide range of patients, including those who are difficult to control, such as elderly patients with isolated systolic hypertension and patients with diabetes. The results of early clinical trials in patients with congestive heart failure have shown that omapatrilat not only improves symptoms but also reduces the risk of and hospitalization and death when compared with ACE inhibitors alone. These results indicate that vasopeptidase inhibition is a promising new strategy in the treatment of hypertension and cardiac diseases.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Dec
pubmed:issn
1699-3993
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
817-28
pubmed:dateRevised
2006-10-26
pubmed:year
2000
pubmed:articleTitle
Omapatrilat: clinical pharmacology.
pubmed:affiliation
Hypertension Unit, Hospital Clinic, Barcelona, Spain.
pubmed:publicationType
Journal Article